Rationale: The Scleroderma Lung Study II (SLS II) demonstrated significant improvements in pulmonary function and dyspnea at 24 months compared with baseline when patients with symptomatic scleroderma-related interstitial lung disease (SSc-ILD) were treated with either cyclophosphamide for 1 year (followed for another year on placebo) or mycophenolate mofetil for 2 years in a randomized, double-blind clinical trial. Physiologic and clinical outcomes of SLS II have been published previously.
Systemic sclerosis (scleroderma) is a complex and life-threatening autoimmune disease associated with tissue fibrosis and small-vessel vasculopathy that targets the skin, lungs, heart, gastrointestinal (GI) tract, peripheral circulation, and musculoskeletal system. Lung involvement has emerged as the leading cause of morbidity and mortality (1) (2) (3) . In Scleroderma Lung Study I (SLS I), treatment with cyclophosphamide (CYC) led to significant improvements in pulmonary outcomes in symptomatic Three granted for randomization Figure 1 . Flowchart of study participants. Eleven subjects were ineligible owing to presence of nodules (n = 6), absence of ground glass (n = 4), and presence of cardiomegaly (n = 1). For those who had baseline and 24-month high-resolution computed tomographic (HRCT) scans available, one of the paired scans from five subjects was not usable, mostly because of incorrect reconstruction interval and slice thickness ranging from 2.5 mm to 5 mm or incomplete coverage of lung. CYC = cyclophosphamide; FU = follow-up; MMF = mycophenolate mofetil.
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patients with scleroderma-related interstitial lung disease (SSc-ILD), although with some adverse events (4) . Several retrospective studies have shown a moderate benefit following treatment of patients with SSc-ILD with mycophenolate mofetil (MMF) (5) . A recent randomized control trial, Scleroderma Lung Study II (SLS-II), demonstrated significant improvements from baseline in lung function and patientcentered outcomes over 24 months in patients receiving either CYC for 1 year (in a dose titrated to 2.0 mg/kg as tolerated followed by placebo for another year) or MMF (in a dose titrated to 1,500 mg twice daily for 2 yr) (6) . Pulmonary function test (PFT) results, particularly the forced vital capacity (FVC), have been studied extensively as a primary measure of treatment efficacy in interstitial lung disease (ILD) clinical trials (4) (5) (6) (7) (8) (9) (10) (11) . Although the response to a 1-year course of treatment with cyclophosphamide in SLS I was statistically significant, the magnitude of the mean changes in FVC percent predicted between patients treated with placebo and those treated with cyclophosphamide was only 2.53% after 12 months of treatment and 4.80% at 18 months (i.e., 6 mo after completing therapy), and there was no difference at 24 months (4, 12). These modest changes raised questions about the clinical significance and durability of cyclophosphamide therapy (12, 13) . High-resolution computed tomography (HRCT) scanning has been used to characterize the nature and extent of SSc-ILD, as well as to predict outcomes (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . The use of changes in quantitative computed tomography (CT) as a measure of treatment efficacy in the setting of SSc-ILD is less well known (25) (26) (27) (28) . In SLS I, the extent of fibrosis at baseline predicted the FVC response to treatment with cyclophosphamide compared with placebo, with those with the most severe fibrosis on the baseline scan showing the greatest response to therapy (29, 30) . Moreover, in a subgroup of patients with baseline and 12-month scans, clear improvement in the quantitative score of SSc-ILD was seen in the cyclophosphamide group, whereas worse scores, on average, were found with placebo (30, 31) .
In SLS II, significantly positive withintreatment responses in FVC percent predicted were found over 24 months compared with baseline with both cyclophosphamide (mean, 3.0%) and mycophenolate (mean, 3.3%) (6) . Similarly, positive responses were found for changes in breathlessness in both treatment arms as demonstrated using the Transition Dyspnea Index (TDI) (2.16 and 1.77 in the cyclophosphamide and mycophenolate arms, respectively [6] , 1.5 being the minimal clinically important improvement for the TDI in SSc-ILD) (32) .
In the present study, we examined the changes in the extent of quantitative parenchymal abnormalities between baseline and 24-month follow-up HRCT scans using a computer-aided diagnostic method in SLS II participants. We hypothesized that treatment with either cyclophosphamide or mycophenolate is associated with stability and/or improvement in HRCT evidence of ILD and that treatmentassociated changes seen on HRCT scans correlate with changes in pulmonary function and patient-reported outcomes.
Methods

Patient Selection
SLS II was a randomized, double-blind, parallel-group trial that enrolled patients from 14 U.S. medical centers with symptomatic SSc-ILD meeting defined criteria for dyspnea (grade 2 on the Mahler Baseline Dyspnea Index) (33) , pulmonary function (FVC, <80% predicted), and HRCT findings (any ground-glass opacity) (6) . There were 142 patients randomly assigned to either mycophenolate (n = 69) or cyclophosphamide (n = 73). PFTs (FVC and single-breath diffusing capacity of the lung for carbon monoxide [DL CO ]) and assessments of the level of dyspnea (Mahler TDI) (33) were performed every 6 months for up to 2 years, whereas HRCT scans were performed at baseline and 24 months only. Cyclophosphamide (Roxane Laboratories) was administered once daily (1.8 to 2.3 mg/kg) for 12 months, and placebo was administered during the 12-to 24-month period. Mycophenolate (Roche Laboratories) was administered twice daily up to a maximum total daily dose of 3.0 g for a total of 2 years (6).
The 126 patients (mycophenolate [n = 63] and cyclophosphamide [n = 63] arms) with acceptable baseline HRCT studies and at least one outcome measure were included in the primary analysis. Acceptable baseline CT studies were defined as being of satisfactory image quality and showing evidence of parenchymal changes associated Figure 1 ). The local institutional review board of each participating clinical center approved the use of images and PFTs. All image management was compliant with the Health Insurance Portability and Accountability Act.
CT Scanning Protocol
Standardized thin-section (,1.25 mm) reduced-dose (80-100 mAs) volumetric HRCT at suspended full inspiration at total lung capacity (TLC) was performed at all sites. Images were acquired using 12 different multidetector CT scanner models from two manufacturers under strict quality control guidelines, including credentialing the scanners, by showing stability of water and air measures on two phantom scans and stability of phantom measures on phantoms scanned within 24 hours of each subject's scan. Patients were scanned at suspended TLC, mostly in the prone position. Of the 102 subjects who had baseline and 24-month follow-up scans, 5 were dropped owing to unusable HRCT scans at either screening or 24 months ( Figure 1 ). Of the 80 subjects with paired HRCT scans who completed the study protocol, all were scanned on the same CT platform with the same acquisition protocol and in the same position.
Quantitative CT Image Analysis
Whole lung and lobes on HRCT images were segmented semiautomatically using an in-house analysis workstation (30) . An independent thoracic radiologist confirmed lobar segmentation. Quantitative CT texturebased disease extent was derived from a previously described supervised texture classification model (27) . Quantitative CT computer-aided diagnostic scores for extent of lung involvement were as follows: quantitative lung fibrosis (QLF), which included fibrotic reticulation patterns only; quantitative honeycomb (QHC); and quantitative ground glass (QGG). Quantitative interstitial lung disease (QILD) scores represented the total ILD pattern and consisted of the sum of all three scores (i.e., QLF 1 QGG 1 QHC). These quantitative CT scores were expressed as a percentage of total lung and individual lobe involvement on 194 scans (paired from 97 patients). Based on previous work involving repeated scans (28) , decreases or increases of 4% or more in QLF or QILD scores in the lobe of maximal involvement and of 2% or more in the whole lung were considered to represent significant worsening or improvement, respectively, whereas scores that remained within these limits were regarded as representing stable disease.
Statistical Analysis
Baseline demographic and clinical characteristics, PFT results, and quantitative CT texture scores are reported as summary statistics. QLF and QILD scores can range from 0 to 100%, with higher scores indicating greater disease extent. After BoxCox tests, QLF and QILD scores were transformed to meet the normality assumption. Paired t tests were used to compare the changes at follow-up from baseline in QLF and QILD scores in whole lung and the most severely involved lobe as the primary radiologic endpoints. A mixedeffect model was used to test the treatmentassociated changes over 24 months in quantitative HRCT scores after adjusting for the baseline characteristics. In secondary analyses, Spearman rank correlations were used to test the association between changes in QLF and QILD scores and changes in both pulmonary function measures and dyspnea scores (expressed as the TDI). These analyses were performed for both treatment groups combined and for each treatment group separately.
Results
Disposition
The disposition of the study population by the availability of technically usable HRCT scans at both baseline and 24 months is shown by treatment group and completion of 24 months of the assigned study drug in Figure 1 . There were 47 and 50 subjects with usable paired 24-month HRCT scans in the cyclophosphamide and mycophenolate arms, respectively. We defined worse, stable, and better changes in QLF and QILD for the most severe lobe as follows: less than 4% = worse; 4% to 24% = stable; less than 24% = better. Using these cut points, 25%, 45%, and 30% of cyclophosphamide (CYC) patients exhibited worse, stable, and better changes in QLF, respectively, whereas 34%, 52%, and 14% of mycophenolate mofetil (MMF) patients showed worse, stable, and better changes in QLF, respectively. Using the same cut points, 27%, 26%, and 47% of CYC patients exhibited worse, stable, and better changes in QILD, respectively, whereas 26%, 34%, and 40% of MMF patients showed worse, stable, and better changes in QILD, respectively. We defined worse, stable, and better changes in QLF and QILD for the whole lung as follows: greater than 2% = worse; 2% to 22% = stable; less than 22% = better. Using these cut points, 28%, 42%, and 30% of CYC patients exhibited worse, stable, and better changes in QLF, respectively, whereas 34%, 62%, and 18% of MMF patients showed worse, stable, and better changes in QLF, respectively. Using the same cut points, 32%, 11%, and 57% of CYC patients exhibited worse, stable, and better changes in QILD, respectively, whereas 26%, 18%, and 56% of MMF patients showed worse, stable, and better changes in QILD, respectively.
Descriptive Summary Statistics
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close to 0, indicating that the QGG amount was close to the difference between QILD and QLF scores.
Changes in QLF, QGG, and QILD scores between 24 months and baseline are shown for subjects with paired CT scans at both time points by treatment arm separately and in both arms combined (pooled group) in Table 2 . These changes are illustrated for QLF and QILD for each arm separately in Figure 2 by the frequency distribution of these changes at intervals of 4% for the changes in the most severely affected lobe and of 2% for the changes in the whole lung. After adjusting for sex and mRSS at baseline, changes in QLF score were stable (mean, 20.003; adjusted 95% confidence interval [CI], 20.012% to 0.01%), whereas QILD scores decreased significantly by a mean (standard error [SE]) of 2.52% (60.76) in whole lung (P = 0.001; adjusted 95% CI, 24.00% to 21.03%). Similarly, in the most severe lobe, changes in QLF score were stable (mean, 1.05; adjusted 95% CI, 21.08% to 3.17%), whereas QILD scores decreased significantly by a mean (SE) of 1.8% (60.85) in whole lung (P = 0.037; mean, 22.51; adjusted 95% CI, 24.19% to 20.13%). Mean duration between the two paired CT scans was 25.1 (SD, 1.9) months. QLF scores of most of the subjects remained stable over the period of the study.
Significant correlations were found between changes in quantitative HRCT scores (QLF and QILD) and changes in percent predicted FVC and TLC over the 24 months of the trial in all subjects with paired HRCT scans (Table 3 ). In contrast, no meaningful correlation was found between the QLF changes and changes in DL CO , whereas improvement in QILD scores in the whole lung did correlate with DL CO , but not in the most severe lobe, and improvement in DL CO in the whole lung. Associations by treatment arms are shown in Table 4 ; no apparent between-treatment differences in these associations were found, except for DL CO , for which changes were correlated with changes in QILD in subjects in the cyclophosphamide arm but not in the mycophenolate arm. Figure 3 shows the 2-year changes in QILD and QLF scores in both the most severely affected lobe and the whole lung in individual subjects by treatment arm. Approximately half of the subjects in both treatment arms had reductions (improvement) or no changes (stability) in both QLF and QILD scores in the most severe lobe, whereas approximately twothirds of the subjects had reductions or no changes in QLF and QILD scores in the Data are presented as Spearman's r (P value). n = 97 pairs for FVC and HRCT; n = 93 pairs for DL CO and HRCT for all patients. For DL CO , n = 44 in cyclophosphamide arm and n = 49 in mycophenolate mofetil arm; for TDI, n = 35 in cyclophosphamide arm and n = 37 in mycophenolate mofetil arm.
whole lung (Figure 3 ). Figure 4 depicts the baseline and 24-month HRCT scans of two representative responders, defined as those with clinically significant reductions in scores, one in the cyclophosphamide arm and the other in the mycophenolate arm. In both subjects, both quantitative radiographic scores and PFTs improved over time.
Discussion
This double-blind, randomized, placebocontrolled clinical trial examined the efficacy of oral cyclophosphamide for 1 year or of mycophenolate mofetil for 2 years for SSc-ILD. Our findings indicate a significant treatment effect of both cyclophosphamide and mycophenolate mofetil on changes in prespecified exploratory outcome quantitative image analysis biomarkers of QLF and QILD scores over a period of 2 years. There was no significant benefit of one treatment over the other in HRCT measures, however, a finding that was supported by similar results in the primary study outcome measures of FVC change over the course of the study (6) . The HRCT changes in structural measures of ILD support the potential clinical effectiveness of both cyclophosphamide and mycophenolate mofetil for progressive SSc-ILD. Both oral cyclophosphamide and mycophenolate have been shown to be effective in one or more randomized controlled trials using FVC as the primary outcome measure (4, 6, 7) . The present analysis provides further evidence that mycophenolate and cyclophosphamide are effective therapeutic agents for SSc-ILD on the basis of observed improvements in parenchymal structure as measured by the changes in the quantitative assessment of the extent of fibrosis and ILD. The response to cyclophosphamide is consistent with that reported in SLS I, in which significant improvements in both QLF and QILD scores were demonstrated for the cyclophosphamide group, whereas scores for fibrosis and ILD generally worsened in the placebo arm, consistent with disease progression in the majority of the latter subjects (28, 30, 31) . 
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In the present study of the SLS II population, there was significant improvement in the extent of ILD on HRCT as measured using the QILD score in those subjects who completed treatment with either mycophenolate or cyclophosphamide in comparison with the scores at baseline, suggesting that both drugs offered therapeutic benefit. In contrast, among those subjects who failed to complete treatment, the extent of fibrosis and ILD tended to worsen, consistent with a significant association of HRCT evidence of changes in lung structure with clinical outcomes with respect to both favorable and unfavorable responses of SSc-ILD to immunosuppressive therapy. Our observations of significant associations between changes in both FVC and TLC and changes in the quantitative radiographic measures of extent of ILD in both treatment arms provide validating evidence that the improvements in the physiologic measures are surrogate indicators of structural improvement in pulmonary fibrosis.
An interesting finding was the relationship between fibrosis and the ORIGINAL RESEARCH response to treatment as measured by QLF and QILD scores. Although the groundglass opacity on HRCT may represent acute alveolitis, it is nonspecific because it might also represent fine intralobular fibrosis (20, 34, 35) . Although in this study QGG did decrease in both the cyclophosphamide and mycophenolate mofetil groups, by 22.56 (1.05) (24.61 to 20.50; P = 0.015) and 23.35 (1.25) (25.80 to 20.88; P = 0.008), respectively, the direction of change could have been progression of either inflammation or fine fibrosis to more obvious fibrosis rather than resolution to normal lung. Thus, no change or actual decreases in QLF appear to be more useful indicators of stabilization or improvement, respectively, in ILD.
An important limitation of this study is the absence of a follow-up HRCT scan at 12 months, thereby preventing our ability to detect changes in CT measures of SSc-ILD during the active phase of one of the treatment arms, namely the cyclophosphamide arm, wherein the active study drug was administered for only 1 year. Moreover, a 12-month follow-up HRCT scan would have allowed a direct comparison of our present findings with those previously reported concerning the impact of cyclophosphamide versus placebo in SLS I on quantitative radiographic measures of fibrosis and ILD assessed at 1 year. The absence of a placebo arm in SLS II is another limitation of the SLS II study design in the interpretation of the clinical significance of the changes over time after active treatment with two immunosuppressive agents. However, the natural history of SSc-ILD would lead one to expect either slow progression or stability rather than actual improvement in the extent of ILD. A further limitation of the present study is the relatively small number of randomized subjects with a second HRCT scan (47 of 73 assigned to cyclophosphamide and 50 of 69 assigned to mycophenolate), together with the withdrawal of a substantial number of randomized subjects from the treatment phase of the trial, such that only 32 and 48 subjects in the cyclophosphamide and mycophenolate arms, respectively, both completed their assigned treatment and had follow-up scans. In addition, four subjects and one subject in the cyclophosphamide and mycophenolate groups, respectively, had at least one unusable scan at either baseline or 24 months, owing to nonvolumetric scans with thick slices or incomplete coverage of the lung on the scan. Furthermore, the fact that a larger number of subjects in the cyclophosphamide arm than in the mycophenolate arm failed to receive a follow-up scan may have affected our ability to assess potential treatment differences in the HRCT findings, although the results of the physiologic measures were comparable between the two treatments (6) . A final limitation is the lack of histopathologic correlation for follow-up changes in quantitative imaging measures. The availability of direct radiologic-pathologic correlation would strengthen the validation of the imaging-based biomarkers beyond the correlations with physiologic measures.
Changes in quantitative HRCT scores of SSc-ILD provide independent validation of the favorable treatment effect produced by both cyclophosphamide and mycophenolate in SLS II, supporting the concept that treatment-related improvements in the 2-year course of FVC percent predicted by both forms of immunosuppressive therapy (cyclophosphamide and mycophenolate) reflect structural changes in lung disease. The HRCT scan findings therefore support the interpretation that cyclophosphamide and mycophenolate, on average, slowed the progression of ILD over a 2-year period and in a substantial minority of the subjects actually resulted in partial resolution of the ILD.
Conclusions
Changes in HRCT outcomes over 24 months were significantly correlated with changes in FVC percent predicted and TLC percent predicted, providing structural evidence of stabilization or improvement in lung fibrosis in support of the physiologic changes in patients with symptomatic SSc-ILD when treated with either mycophenolate for 2 years or cyclophosphamide for 1 year.
Results of the present study suggest that the incorporation of follow-up HRCT scans in controlled clinical trials of interventions in patients with SSc-ILD (and potentially in other interstitial pneumonitides) might prove to be a useful adjunct to conventional physiologic and patient-centered endpoints. n
